Hidradenitis Suppurativa - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 51 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Hidradenitis Suppurativa - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Hidradenitis Suppurativa - Pipeline Review, H2 2014', provides an overview of the Hidradenitis Suppurativa's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hidradenitis Suppurativa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hidradenitis Suppurativa and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hidradenitis Suppurativa and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hidradenitis Suppurativa products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hidradenitis Suppurativa pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hidradenitis Suppurativa
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hidradenitis Suppurativa pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hidradenitis Suppurativa Overview 6
Therapeutics Development 7
Pipeline Products for Hidradenitis Suppurativa - Overview 7
Pipeline Products for Hidradenitis Suppurativa - Comparative Analysis 8
Hidradenitis Suppurativa - Therapeutics under Development by Companies 9
Hidradenitis Suppurativa - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Hidradenitis Suppurativa - Products under Development by Companies 13
Hidradenitis Suppurativa - Companies Involved in Therapeutics Development 14
AbbVie Inc. 14
Delenex Therapeutics AG 15
Johnson & Johnson 16
Hidradenitis Suppurativa - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
adalimumab - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
adalimumab biosimilar - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
DLX-105 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
DLX-2751 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ustekinumab - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Hidradenitis Suppurativa - Recent Pipeline Updates 34
Hidradenitis Suppurativa - Dormant Projects 43
Hidradenitis Suppurativa - Discontinued Products 44
Hidradenitis Suppurativa - Product Development Milestones 45
Featured News & Press Releases 45
Oct 13, 2014: AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress 45
Sep 11, 2014: AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy of HUMIRA� (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease 46
Oct 03, 2013: AbbVie Presents Phase II Data Evaluating the Efficacy of HUMIRA in Patients with Hidradenitis Suppurativa 47
Mar 15, 2012: Abbott Announces Patient Enrollment In Two Phase III Studies Of HUMIRA For Moderate To Severe Hidradenitis Suppurativa 48
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Tables
Number of Products under Development for Hidradenitis Suppurativa, H2 2014 7
Number of Products under Development for Hidradenitis Suppurativa - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Hidradenitis Suppurativa - Pipeline by AbbVie Inc., H2 2014 14
Hidradenitis Suppurativa - Pipeline by Delenex Therapeutics AG, H2 2014 15
Hidradenitis Suppurativa - Pipeline by Johnson & Johnson, H2 2014 16
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Stage and Target, H2 2014 19
Number of Products by Stage and Mechanism of Action, H2 2014 21
Number of Products by Stage and Route of Administration, H2 2014 23
Number of Products by Stage and Molecule Type, H2 2014 25
Hidradenitis Suppurativa Therapeutics - Recent Pipeline Updates, H2 2014 34
Hidradenitis Suppurativa - Dormant Projects, H2 2014 43
Hidradenitis Suppurativa - Discontinued Products, H2 2014 44